Mouse Study Maps How Early Mitochondrial Stress Protected Adult Hearts

A Salk Institute study has identified a cellular pathway through which brief mitochondrial stress during embryonic development protected mice from later heart damage caused by the chemotherapy drug doxorubicin. The findings, published in Science Advances, provide a mechanistic look at mitohormesis—a process in which limited mitochondrial stress triggers adaptations that can improve resilience in model organisms.

The researchers used a mouse strain in which a mitochondrial antioxidant system could be temporarily reduced. They lowered that protection during embryonic development and restored it before birth. After the mice reached adulthood, they were treated with doxorubicin, which can damage mitochondria and induce heart failure.

Mice exposed to the early mitochondrial stress were less vulnerable to doxorubicin’s cardiac toxicity than littermate controls, according to the study as reported by Medical Xpress. The experiment extended earlier work from the same laboratory, which had found that a similar developmental stress response in mouse liver resulted in more mitochondria, lower production of reactive oxygen species (ROS), and activation of several antioxidant systems later in life.

To investigate how the heart-protective effect arose, the team conducted additional experiments in mouse embryonic fibroblasts. Temporarily disrupting the mitochondrial antioxidant system caused superoxide, a form of mitochondrial ROS, to accumulate. That buildup inhibited an enzyme involved in energy production, leading citrate to accumulate inside mitochondria.

Citrate then moved out of the mitochondria and was converted into acetyl-CoA, a molecule involved in epigenetic regulation. The researchers reported that this sequence produced durable epigenetic changes associated with cellular protection and resilience to later stress. In this model, citrate functioned as an intermediary signal linking mitochondrial stress to changes elsewhere in the cell.

The findings also highlight why the biological effects of ROS may be more complicated than simple damage. High levels of mitochondrial ROS can harm cells, while lower levels can act as signals. The study’s authors said that understanding this signaling pathway could help guide research into approaches that influence mitochondrial and antioxidant responses together, rather than targeting individual ROS molecules.

The work remains preclinical. It involved mice and mouse-derived cells, and it does not establish that inducing mitochondrial stress or using citrate would protect human hearts, delay human aging, or extend human lifespan. The researchers said future studies could examine whether mitohormesis can be induced after embryonic development, whether citrate itself can reproduce the protective response, and whether the findings apply to more human-relevant tissue models.